[1] MEMBERS A F,MANCIA G,FAGARD R,et al.2013 ESH/ESC Guidelines for the management of arterial hypertension[J].Eur Heart J,2013,31(10):1925-1938.
[2] World Health Organization(WHO).Cardiovascular disease.[2016-02-15].http://www.who.int/cardiovascular diseases/en/.
[3] MARTÍNTIMÓN I,SEVILLANOCOLLANTES C,SEGURAGALINDO A.Type 2 diabetes and cardiovascular disease:Have all risk factors the same strength?[J].World J Diabetes,2014,5(4):444-470.
[4] AYLSWORTH A,DEAN Z,VANNORMAN C,et al.Dapagliflozin for the treatment of type 2 diabetes mellitus[J].Ann Pharmacother,2014,48(9):1202-1208.
[5] VINCENT A O,PARIMALARANIE Y,BENJAMIN L M,et al.Uncontrolled hypertension and its determinants in patients with concomitant type 2 diabetes mellitus(T2DM)in rural South Africa[J].Plos One,2016,11(3):e0150033.
[6] ASSOCIATION A D.Cardiovascular disease and risk management[J].Diabetes Care,2015,39 suppl(1):S60-71.
[7] RYDEN L,GRANT PJ,ANKER SD,et al.ESC guidelines on diabetes,pre-diabetes,and cardiovascular diseases developed in collaboration with the EASD—summary[J].Diabetes Vasc Dis Res,2014,11(3):133-173.
[8] JAMES PA,OPARIL S,CARTER BL,et al.2014 evidence-based guideline for the management of high blood pressure in adults:report from the panel members appointed to the Eighth Joint National Committee(JNC 8)[J].JAMA,2014,311(5):507-520.
[9] CASAGRANDE S S,FRADKIN J E,SAYDAH S H,et al.The prevalence of meeting A1C,blood pressure,and LDL goals among people with diabetes,1988-2010[J].Diabetes Care,2013,36(8):2271-2279.
[10] GALLO L A,WRIGHT E M,VALLON V.Probing SGLT2 as a therapeutic target for diabetes:basic physiology and consequences[J].Diabetes Vasc Dis Res,2015,12(2):78-89.
[11] INZUCCHI S E,ZINMAN B,WANNER C,et al.SGLT-2 inhibitors and cardiovascular risk:proposed pathways and review of ongoing outcome trials[J].Diabetes Vasc Dis Res.2015,12(2):90-100.
[12] VASILAKOU D,KARAGIANNIS T,ATHANASIADOU E,et al.Sodium-glucose cotransporter 2 inhibitors for type 2 diabetes:a systematic review and meta-analysis[J].Ann Intern Med.2013,159(4):262-274.
[13] BAILEY C J,GROSS J L,PIETERS A,et al.Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin:a randomised,double-blind,placebo-controlled trial[J].Lancet,2010,375(9733):2223-2233.
[14] HARING HU,MERKER L,SEEWALDT-BECKER E,et al.Empagliflozin as add-on to metformin in patients with type 2 diabetes:a 24-week,randomized,double-blind,placebo-controlled trial[J].Diabetes Care.2014,37(6):1650-1659.
[15] WILDING J P.A safety evaluation of canagliflozin:a first-in-class treatment for type 2 diabetes[J].Expert Opinion on Drug Safety,2014,13(11):1535-1544.
[16] MONAMI M,NARDINI C,MANNUCCI E.Efficacy and safety of sodium glucose co-transport-2 inhibitors in type 2 diabetes:a meta-analysis of randomized clinical trials[J].Diabetes Obes Metab,2014,16(5):457-466.
[17] PEENE B,BENHALIMA K.Sodium glucose transporter protein 2 inhibitors:focusing on the kidney to treat type 2 diabetes[J].Ther Adv.Endocrinol & Metab.2014,5(5):124-136.
[18] CHERNEY D Z I,PERKINS B A,SOLEYMANLOU N,et al.Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus[J].Circulation.2014,129(5):587-597.
[19] CHERNEY DZ I,PERKINS B A,SOLEYMANLOU N,et al.The effect ofempagliflozin on arterial stiffness and heart rate variability in subjects with uncomplicated type 1 diabetes mellitus[J].Cardiovasc Diabetol.2014,13(1):28.
[20] LYTVYN Y,PERKINS B A,CHERNEY D Z I.Uric acid as a biomarker and a therapeutic target in diabetes[J].Can J Diabetes.2015,39(3):239-246.
[21] LYTVYN Y,SKRTIC M,YANG G K,et al.Glycosuria-mediated urinary uric acid excretion in patients with uncomplicated type 1 diabetes mellitus[J].Am J Physiol Renal Physiol.2014,308(2):77-83.
[22] BAKER W L,SMYTH L R,RICHE D M,et al.Effects of sodium-glucose co-transporter 2 inhibitors on blood pressure:A systematic review and meta-analysis[J].Am Soc Hypertens.2014,8(4):262-275.
[23] WILDING JP,CHARPENTIER G,HOLLANDER P,et al.Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sulphonylurea:a randomised trial[J].Int Clin Pract.2013,67(12):1267-1282.
[24] RAJASEKERAN H,LYTVYN Y,CHERNEY D Z I.Sodium-glucose cotransporter 2 inhibition and cardiovascular risk reduction in patients with type 2 diabetes:the emerging role of natriuresis[J].Kidney Int.2016,89(3):524-526.
[25] PERKINS B A,UDELL J A,CHERNEY D Z.No need to sugarcoat the message:Is cardiovascular risk reduction from SGLT2 inhibition related to natriuresis?[J].Am J Kidney Dis,2016,68(3):349-352.
[26] TIKKANEN I,NARKO K,ZELLER C,et al.Empagliflozin reduces blood pressure in patients with type 2 diabetes and hypertension[J].Diabetes Care,.2014,38(3):420-428.
[27] TOWNSEND R R,ISRAEL MACHIN M D,REN J,et al.Reductions in mean 24-hour ambulatory blood pressure after 6-week treatment with canagliflozin in patients with type 2 diabetes mellitus and hypertension[J].J Clin Hypertens.2016,18(1):43-52.
[28] HEERSPINK HJ,PERKINS BA,FITCHETT DH,et al.Sodium glucose cotransporter 2 inhibitors in the treatment of diabetes mellitus:cardiovascular and kidney effects,potential mechanisms,and clinical applications[J].Circulation,2016,134(10):752-772
[29] ROSENSTEIN R,HOUGH A.Empagliflozin,cardiovascular outcomes,and mortality in type 2 diabetes[J].NEJM,2015,373(22):2117-2128.
[30] RUDOSFKY G,ROHWEDDER K,BALYCHEVA I,et al.Genitalinfektionen und zusammenhang mit dem body-mass-index bei patienten mit typ-2-diabetes-mellitus unter dapagliflozin[J].Diabetologie Und Stoffwechsel.2016,11(S 01):947.
[31] DESOUZA C V,GUPTA N,PATEL A.Cardiometabolic effects of a new class of antidiabetic agents[J].Clin Ther.2015,37(6):1178-1194.
[32] BAILEY C J,GROSS J L,PIETERS A,et al.Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin:a randomised,double-blind,placebo-controlled trial[J].Lancet,2010,375(9733):2223-2233.
[33] DZIUBA J,ALPERIN P,RACKETA J,et al.Modeling effects of SGLT‐2 inhibitor dapagliflozin treatment versus standard diabetes therapy on cardiovascular and microvascular outcomes[J].Diabetes Obesity & Metabolism,2014,16(7):628-635.
[34] WANNER C,INZUCCHI S E,LACHIN J M,et al.Empagliflozin and progression of kidney disease in type 2 diabetes[J].NEJM,2016,375:323-334. |
